DexCom, Inc. (NASDAQ:DXCM) – Equities research analysts at Jefferies Financial Group increased their Q2 2021 earnings per share (EPS) estimates for shares of DexCom in a report issued on Thursday, April 29th. Jefferies Financial Group analyst R. Denhoy now anticipates that the medical device company will earn $0.51 per share for the quarter, up from their previous forecast of $0.47. Jefferies Financial Group also issued estimates for DexCom’s Q3 2021 earnings at $0.71 EPS, Q4 2021 earnings at $0.70 EPS, FY2021 earnings at $2.25 EPS, Q1 2022 earnings at $0.66 EPS, Q2 2022 earnings at $0.78 EPS, Q3 2022 earnings at $0.89 EPS, Q4 2022 earnings at $1.07 EPS, FY2022 earnings at $3.40 EPS and FY2023 earnings at $4.70 EPS.
DXCM has been the topic of a number of other research reports. Canaccord Genuity raised their price objective on shares of DexCom from $445.00 to $455.00 and gave the stock a “buy” rating in a report on Friday, April 30th. TheStreet lowered shares of DexCom from a “b-” rating to a “c” rating in a research report on Thursday, April 29th. Raymond James lifted their price objective on shares of DexCom from $449.00 to $466.00 and gave the company an “outperform” rating in a research report on Friday, April 30th. Piper Sandler lifted their price objective on shares of DexCom from $465.00 to $500.00 and gave the company an “overweight” rating in a research report on Friday, January 29th. Finally, Oppenheimer lifted their price objective on shares of DexCom from $415.00 to $449.00 and gave the company an “outperform” rating in a research report on Friday, February 12th. One research analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $454.94.
DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 29th. The medical device company reported $0.33 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.02. DexCom had a net margin of 12.69% and a return on equity of 27.29%.
Several hedge funds have recently made changes to their positions in DXCM. Evolution Wealth Advisors LLC lifted its holdings in shares of DexCom by 53.7% during the 1st quarter. Evolution Wealth Advisors LLC now owns 83 shares of the medical device company’s stock worth $30,000 after acquiring an additional 29 shares during the period. Fieldpoint Private Securities LLC purchased a new position in shares of DexCom during the 4th quarter worth about $35,000. Chiron Capital Management LLC purchased a new position in shares of DexCom during the 3rd quarter worth about $41,000. GVO Asset Management Ltd purchased a new position in shares of DexCom during the 1st quarter worth about $48,000. Finally, TCI Wealth Advisors Inc. increased its position in DexCom by 21.1% during the 1st quarter. TCI Wealth Advisors Inc. now owns 138 shares of the medical device company’s stock worth $50,000 after purchasing an additional 24 shares in the last quarter. Institutional investors and hedge funds own 94.06% of the company’s stock.
In other DexCom news, EVP Patrick Michael Murphy sold 500 shares of the company’s stock in a transaction dated Monday, April 26th. The shares were sold at an average price of $415.83, for a total value of $207,915.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Steven Robert Pacelli sold 1,079 shares of the company’s stock in a transaction dated Friday, April 23rd. The shares were sold at an average price of $410.31, for a total transaction of $442,724.49. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 34,192 shares of company stock worth $12,681,786. 0.69% of the stock is owned by insiders.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system.
Read More: Technical Analysis
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.